Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms
This article was originally published in The Pink Sheet Daily
Executive Summary
South Korea's Ministry of Health and Welfare announced measures to drastically cut drug prices, while also committing to support innovation-focused companies through tax credits and preferential pricing, but both domestic and global pharma reacted with strongly worded opposition.
You may also be interested in...
Korea's Health Ministry To Unveil Steeper Price Cuts After Patent Loss; Generics Could Be The Big Loser
SEOUL - Korea's Ministry of Health and Welfare confirmed that it is preparing a new pricing system to further cut prices of both innovative products and generics. The plan could deal a blow to Korea's generic-dependent pharmas by eventually eliminating price differences of generics and off-patent brands under Korea's national health insurance
Korea's Health Ministry Gets In The Act To Generate Korean Innovation For U.S. Markets
SEOUL - South Korea's Ministry of Health and Welfare has selected 21 Korean pharmaceutical manufacturers and 17 medical equipment firms to support these companies in the development of globally competitive new drugs, marketing efforts and U.S. FDA approvals needed for their advancement into the U.S. market
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.